Researcher Profile

Researcher Profile

Monika Joshi, MD, MRCP

Monika Joshi, MD, MRCP

Associate Professor, Department of Medicine
Division of Hematology and Oncology
Assistant Professor, Department of Medicine
Scientific Program:Next-Generation Therapies
Disease Teams:
Genitourinary Cancer

Research Interests

Dr. Monika Joshi’s research focus is in the field of genitourinary tumors, particularly in the field of immunotherapy and targeted therapy.

  • Therapeutics
  • Neoplasms
  • Non-Small Cell Lung Carcinoma
  • Survival
  • Immunotherapy
  • Prostatic Neoplasms
  • Renal Cell Carcinoma
  • Urinary Bladder Neoplasms
  • Smokers
  • Smoking
  • Drug Therapy
  • Mutation

Clinical Trials

Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043
A Phase III Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib plus JNJ-63723283 (Cetrelimab), an Anti-PD-1 Monoclonal Antibody, in Subjects with Metastatic or Locally Advanced Urothelial Cancer with Selected FGFR Gene Alterations
Targeting PIM1 and CDK4/6 Kinases in Renal Cell Carcinoma (PICKRCC): A Phase Ib study of Abemaciclib in Combination with Sunitinib in metastatic RCC
Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial
A Phase III Randomized Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients with Previously Untreated Advanced Renal Cell Carcinoma
Phase III Randomized Trial Of Concurrent Chemoradiotherapy With or Without Atezoluzumab in Localized Muscle Invasive Bladder Cancer
One Time Tissue and Blood Collection from Patients with Lung Cancer at Risk for Developing Lung Cancer
Observational Study to Determine the Differences in Molecular Characterization between Smokers vs. Non-smokers in Patients with Stage IV Bladder Cancer and their Correlation with Clinical Outcome
Tissue and Blood Collection from Patients with Suspected Lung Cancer

Recent Publications


Khaki, AR, Li, A, Diamantopoulos, LN, Bilen, MA, Santos, V, Esther, J, Morales-Barrera, R, Devitt, M, Nelson, A, Hoimes, CJ, Shreck, E, Assi, H, Gartrell, BA, Sankin, A, Rodriguez-Vida, A, Lythgoe, M, Pinato, DJ, Drakaki, A, Joshi, M, Isaacsson Velho, P, Hahn, N, Liu, S, Alonso Buznego, L, Duran, I, Moses, M, Jain, J, Murgic, J, Baratam, P, Barata, P, Tripathi, A, Zakharia, Y, Galsky, MD, Sonpavde, G, Yu, EY, Shankaran, V, Lyman, GH & Grivas, P 2020, 'Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors', Cancer, vol. 126, no. 6, pp. 1208-1216.
Dudek, AZ, Liu, LC, Gupta, S, Logan, TF, Singer, EA, Joshi, M, Zakharia, YN, Lang, JM, Schwarz, JK, Al-Janadi, A & Alva, AS 2020, 'Phase Ib/II clinical trial of pembrolizumab with bevacizumab for metastatic renal cell carcinoma: BTCRC-GU14-003', Journal of Clinical Oncology, vol. 38, no. 11, pp. 1138-1145.
Yin, M, Grivas, P, Wang, QE, Mortazavi, A, Emamekhoo, H, Holder, SL, Drabick, JJ, Woo, MSA, Pal, S, Vasekar, M, Folefac, E, Clinton, SK, Monk, P & Joshi, M 2020, 'Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer', Oncologist.


Voss, MH, Bhatt, RS, Vogelzang, NJ, Fishman, M, Alter, RS, Rini, BI, Beck, JT, Joshi, M, Hauke, R, Atkins, MB, Burgess, E, Logan, TF, Shaffer, D, Parikh, R, Moazzam, N, Zhang, X, Glasser, C, Sherman, ML & Plimack, ER 2019, 'A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma', Cancer, vol. 125, no. 14, pp. 2400-2408.
Joshi, A, Hillwig-Garcia, J, Joshi, M, Lehman, E, Khan, A, Llorente, A & Haidet, P 2019, 'Comics as an Educational Tool on a Clinical Clerkship', Academic Psychiatry, vol. 43, no. 3, pp. 290-293.
Yin, M, Zhao, J, Monk, P, Martin, D, Folefac, E, Joshi, M, Jin, N, Mortazavi, A, Verschraegen, C & Clinton, S 2020, 'Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in high-risk localized prostate cancer', Cancer medicine, vol. 9, no. 1, pp. 27-34.
Zhu, J, Hussain, M, Joshi, A, Truica, CI, Nesterova, D, Collins, J, Saunders, EFH, Hayes, M, Drabick, JJ & Joshi, M 2020, 'Effect of creative writing on mood in patients with cancer', BMJ Supportive and Palliative Care, vol. 10, no. 1, pp. 64-67.
Loriot, Y, Necchi, A, Park, SH, Garcia-Donas, J, Huddart, R, Burgess, E, Fleming, M, Rezazadeh, A, Mellado, B, Varlamov, S, Joshi, M, Duran, I, Tagawa, ST, Zakharia, Y, Zhong, B, Stuyckens, K, Santiago-Walker, A, De Porre, P, O'Hagan, A, Avadhani, A & Siefker-Radtke, AO 2019, 'Erdafitinib in locally advanced or metastatic urothelial carcinoma', New England Journal of Medicine, vol. 381, no. 4, pp. 338-348.
Zaleski, M, Gogoj, A, Walter, V, Raman, JD, Kaag, M, Merrill, SB, Drabick, J, Joshi, M, Holder, S, DeGraff, DJ & Warrick, JI 2019, 'Mitotic activity in noninvasive papillary urothelial carcinoma: its value in predicting tumor recurrence and comparison with the contemporary 2-tier grading system', Human Pathology, vol. 84, pp. 275-282.
Joshi, M, Warrick, JI, Yin, M, Holder, SL & Drabick, JJ 2019, 'Need for a personalized approach for muscle invasive bladder cancer: Role of tumor biology in response to neoadjuvant chemotherapy', Translational Andrology and Urology, vol. 8, pp. S99-S103.


Yin, M, Grivas, P, Emamekhoo, H, Mendiratta, P, Ali, S, Hsu, JA, Vasekar, M, Drabick, JJ, Pal, S & Joshi, M 2018, 'ATM/RB1 mutations predict shorter overall survival in urothelial cancer', Oncotarget, vol. 9, no. 24, pp. 16891-16898.


Venur, VA, Joshi, M, Nepple, KG & Zakharia, Y 2017, 'Spotlight on nivolumab in the treatment of renal cell carcinoma: Design, development, and place in therapy', Drug Design, Development and Therapy, vol. 11, pp. 1175-1182.


Pizzola, C, Rizvi, SM & Joshi, M 2016, 'A new era of immunotherapy in prostate cancer', Current Molecular Pharmacology, vol. 9, no. 3, pp. 217-225.
Al-Marrawi, MY, Mackley, HB, Ali, S, Wagner, H, Joshi, M, Holder, S, Kaag, M, Mallon, C, Talamo, G & Drabick, JJ 2016, 'Consolidation With Radiation or Concurrent Chemo-Radiation After Chemotherapy Results in Durable Complete Remissions of Isolated Nodal Recurrences of Urothelial Cancer: A Case Series and Review', Clinical Genitourinary Cancer, vol. 14, no. 4, pp. e393-e399.
Zheng, H, Liu, X, Zhang, J, Rice, SJ, Wagman, M, Kong, Y, Zhu, L, Zhu, J, Joshi, M & Belani, CP 2016, 'Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer', Oncotarget, vol. 7, no. 35, pp. 56233-56240.
Vasekar, M, Degraff, D & Joshi, M 2016, 'Immunotherapy in bladder cancer', Current Molecular Pharmacology, vol. 9, no. 3, pp. 242-251.
Joshi, M, Millis, SZ, Arguello, D, Holder, SL, Lamm, D, Reddy, S, Belani, C, Drabick, JJ & Vogelzang, NJ 2018, 'Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers', European Urology Focus, vol. 4, no. 1, pp. 94-97.
Yin, M, Joshi, M, Meijer, RP, Glantz, M, Holder, S, Harvey, HA, Kaag, M, Van De Putte, EEF, Horenblas, S & Drabick, JJ 2016, 'Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and two-step meta-analysis', Oncologist, vol. 21, no. 6, pp. 708-715.
Joshi, M, Pal, SK & Drabick, JJ 2016, 'Novel approaches in cancer immunotherapy - A light at the end of the tunnel', Discovery Medicine, vol. 21, no. 118.
Joshi, M, Vasekar, M, Grivas, P, Emamekhoo, H, Hsu, JA, Miller, VA, Stephens, PJ, Ali, SM, Ross, JS, Zhu, J, Warrick, J, Drabick, JJ, Holder, SL, Kaag, M, Li, M & Pal, SK 2016, 'Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma', Oncotarget, vol. 7, no. 32, pp. 52442-52449.
Yin, M, Wang, W, Rosenberg, J, Kaag, MG, Joshi, M, Holder, S, Tuanquin, L & Drabick, J 2016, 'Targeted Therapy in Collecting Duct Carcinoma of the Kidney: A Case Report and Literature Review', Clinical Genitourinary Cancer, vol. 14, no. 2, pp. e203-e206.

Clinical Trials Search

Children (age < 18 years)
Adults (age >= 18 years)